Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Epilepsy affects about 50 million people worldwide, making it one of the most common neurological disorders. In India, nearly ...

With NIH support, biomedical engineer Sri Sarma develops neurotechnologies to improve understanding and treatment of epilepsy ...

A 21-year-old man, who had been suffering from epilepsy for 10 years, was finally cured of the neurological disease after an ...

Epilepsy is a seizure disorder that is described by the International League Against Epilepsy as two unprovoked seizures that ...

This article is authored by Dr Amit Kumar Agarwal, senior consultant, neurosciences, neurology and stroke medicine, Amrita ...

A real-world study supports cenobamate as an effective option for patients with drug-resistant epilepsy even after multiple ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

The drug, called tofacitinib, also restores short-term and working memory lost to epilepsy in the mice and reduces ...

A new technique involving ultra-powerful MRI scanners could help doctors identify tiny differences in the brains of people ...